Medicare expands lung cancer screening access for seniors

What it does

This bill amends Medicare law to allow the Secretary of Health and Human Services to cover additional lung cancer screening tests beyond those currently covered, provided they are FDA-cleared or approved and furnished to appropriate individuals. The Secretary sets frequency, payment limits, and eligibility criteria using the standard national coverage determination process, with input from preventive-health experts.

Why we flagged it

The bill's sole operative mechanism is to expand Medicare's authority to cover new lung cancer screening tests. It is a straightforward public-health measure that broadens preventive-service coverage without restricting existing benefits or imposing new costs on beneficiaries.

What the text implies

• The Secretary's discretion to determine 'appropriate individuals' and 'appropriate' frequency and payment limits is broad and not defined in the bill itself; implementation will depend on regulatory guidance and may affect which beneficiaries qualify and how often they can be screened.
• The bill exempts new lung cancer screening tests from the requirement in Section 1861(ddd)(3)(B), which normally applies to preventive services — the effect of this exemption depends on what that section requires and is not visible in this text alone.
• Expansion of Medicare coverage for new screening tests may increase demand for diagnostic imaging and follow-up services, with downstream cost implications for the Medicare program not quantified in the bill.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain access to additional lung cancer screening tests at no out-of-pocket cost, potentially enabling earlier detection and better health outcomes. The bill does not restrict existing coverage or impose new costs on beneficiaries; it only expands the Secretary's authority to add new tests as they become available and meet FDA standards.

Who stands to gain

• diagnostic imaging providers (CT scan, low-dose CT manufacturers and operators)
• healthcare systems and hospitals offering lung cancer screening
• FDA-cleared medical device manufacturers developing new lung cancer screening tests

Named in the bill

Medicare (Title XVIII, Social Security Act), Secretary of Health and Human Services, Food and Drug Administration (FDA), Agency for Healthcare Research and Quality (AHRQ), Section 1834(n), Social Security Act, National Coverage Determination (NCD) 210.14, Section 1861(ddd)(3)(B), Social Security Act

Where it stands

9 cosponsors: 6 Democrats, 3 Republicans.

• Feb 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 18, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 9 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,950,000 in lobbying spend. A filing names 1 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Vern Buchanan, the sponsor, reported $544,700 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings
• Pritikin Icr — $90,000 on 2 filings
• Delfi Diagnostics — $60,000 on 2 filings
• Delfi Diagnostics — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.